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We conducted a case-control study of adults with bac-
teremic pneumococcal pneumonia to identify factors asso-
ciated with macrolide resistance. Study participants were
identified through population-based surveillance in a 5-
county region surrounding Philadelphia. Forty-three hospi-
tals contributed 444 patients, who were interviewed by
telephone regarding potential risk factors. In multivariable
analyses, prior exposure to a macrolide antimicrobial agent
(odds ratio [OR] 2.8), prior flu vaccination (OR 2.0), and
Hispanic ethnicity (OR 4.1) were independently associated
with an increased probability of macrolide resistance, and a
history of stroke was independently associated with a
decreased probability of macrolide resistance (OR 0.2).
Fifty-five percent of patients with macrolide-resistant infec-
tions reported no antimicrobial drug exposure in the pre-
ceding 6 months. Among patients who reported taking
antimicrobial agents in the 6 months preceding infection,
failure to complete the course of prescribed drugs was
associated with an increased probability of macrolide
resistance (OR 3.4).
S
treptococcus pneumoniae is the leading cause of com-
munity-acquired pneumonia in adults. Bacteremic
pneumococcal pneumonia is among the most serious
forms of pneumococcal disease, and incidence rises
steeply with advancing age (1). Although considerable
controversy exists about the clinical impact of pneumococ-
cal drug resistance (2), the prevalence of single-drug and
multidrug–resistant pneumococci has increased in the last
2 decades (3,4). Drug-resistant pneumococci clearly
emerge under the selective forces of antibacterial drugs
used in the population. Still, the precise nature of these
selection mechanisms and the risk associated with differ-
ent types of exposures are not well defined.
Pneumococcal resistance to macrolides is a problem
because macrolides are among the most common oral
drugs used to treat patients with community-acquired
pneumonia (5). A recent study found that patients with
macrolide-resistant pneumococcal bacteremia were sub-
stantially more likely to have been exposed to macrolide
therapy before hospitalization than were patients with
macrolide-susceptible pneumococcal bacteremia (6).
Since most initial therapy of community-acquired pneu-
monia is empiric, estimating the probability of macrolide-
resistant pneumococcal disease is necessary to select
appropriate therapy. Indeed, current treatment guidelines
recommend not prescribing macrolide therapy alone for
patients with community-acquired pneumonia if they
report exposure to macrolides within the 3 months preced-
ing the onset of illness (7).
We conducted a population-based case-control study to
identify clinical and demographic factors independently
associated with macrolide-resistant bacteremic pneumo-
coccal pneumonia in adults. We used a detailed multistage
interview method to elicit in-depth histories of exposure to
antimicrobial agents to examine whether disease probabil-




We conducted a case-control study within a network of
hospitals conducting prospective population-based sur-
veillance for bacteremic pneumococcal pneumonia in
adults in southeastern Pennsylvania from December 1,
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pitalized adults with macrolide-resistant bacteremic pneu-
mococcal pneumonia, and controls were all hospitalized
adults with macrolide-susceptible bacteremic pneumococ-
cal pneumonia.
Study Site
This study was conducted within the 5-county region
surrounding Philadelphia, Pennsylvania: Bucks, Chester,
Delaware, Montgomery, and Philadelphia Counties. The
adult population (age >18 years) of this region is 2,881,132
(US Census 2000). At the start of the surveillance period,
46 acute-care hospitals served this region; 43 of them par-
ticipated in this study. Of the remaining 3 hospitals, 2 were
small hospitals closed to external studies, and 1 was a larg-
er academic hospital that was unable to participate.
Study Participants
Inclusion criteria for the study were persons who 1)
were >18 years of age, 2) had at least 1 blood culture that
grew S. pneumoniae drawn within 48 hours of hospital
admission, 3) resided in 1 of the 5 counties, and 4) had a
bacterial isolate confirmed in our laboratory as S. pneumo-
niae (see below). Study participants were further restricted
on the basis of physician report to those patients with radi-
ographic evidence of an acute respiratory infection.
Exclusion criteria for the case-control study included evi-
dence of bacterial meningitis (cerebrospinal fluid [CSF]
growth of S. pneumoniae or CSF findings compatible with
bacterial meningitis) or hospitalization within 10 days pre-
ceding the index hospitalization. Study participants who
died during hospitalization were included in this study;
information about them was collected by interviewing a
suitable proxy respondent.
Study participants were identified by microbiology lab-
oratory personnel at each participating hospital. Whenever
laboratory personnel identified a blood culture with
growth of S. pneumoniae, research staff contacted the
physician of record to determine the patient’s eligibility.
Eligible participants (or proxies in cases of mental incom-
petence or death) were then approached for study enroll-
ment at a time determined by the treating physician
(typically after hospital discharge). Participants were
mailed informational study materials and then contacted
by phone to provide consent for study participation and
complete a telephone interview.
Data Collection
Trained telephone interviewers completed a telephone
interview with each study participant that covered demo-
graphic and clinical areas. Questions focused on the demo-
graphic and clinical status of the patient immediately
before hospitalization for pneumococcal pneumonia. A
multistep strategy was used to obtain the most complete
drug histories possible. A phased approach was employed
in which the interviewer first asked open-ended questions
about use of drugs, then asked indication-specific ques-
tions about medications used (e.g., for respiratory tract
infections, urinary tract infection) and, finally, named
antimicrobial drugs by brand and generic names while the
participant referred to photo hand cards (mailed to the par-
ticipants in advance) that displayed the study drugs of
interest. In prior research, including a study of antimicro-
bial drug recall, each of these steps has dramatically
increased drug recall (8–11). Participants were asked to
distinguish antimicrobial agents that were being taken at
the time of hospitalization from those drugs that were
taken for illnesses preceding the onset of pneumococcal
pneumonia. We focused on patient self-report of prior
antimicrobial drug exposure to mimic the information that
would be available at the time of diagnosis and empiric
treatment decisions. However, we also contacted the pri-
mary care physicians of study participants to obtain docu-
mentation of antimicrobial agents prescribed in the
6-month period preceding the hospitalization for pneumo-
coccal pneumonia. In addition, since study participants
were interviewed at home, we asked them to examine any
medication bottles that they still possessed to verify the
name of the drug and to determine if any medications were
unfinished.
Microbiologic Data Collection
Pneumococcal blood isolates were transported to a cen-
tral laboratory at the Hospital of the University of
Pennsylvania for analysis. Isolates were re-identified to
confirm that they were pneumococci on the basis of colony
shape and hemolytic activity, Gram stain appearance, cata-
lase reaction, bile solubility, and optochin susceptibility
(12).
Confirmed isolates of S. pneumoniae were screened for
susceptibility to oxacillin, erythromycin, clindamycin,
tetracycline, trimethoprim-sulfamethoxazole, and lev-
ofloxacin by using the Clinical and Laboratory Standards
Institute (CLSI, formerly National Committee for Clinical
Laboratory Standards) disk-diffusion procedure (13).
Isolates that demonstrated reduced susceptibility to any
drug were confirmed by using a Food and Drug
Administration–cleared and CLSI-compliant microbroth
dilution testing method (Sensititer 96 well plate, Trek
Diagnostics Systems, Inc., Cleveland, OH, USA) for S.
pneumoniae. Because the highest erythromycin micro-
broth MICs that could be measured with the assay were 4
µg/mL, additional testing was performed on all erythromy-
cin-resistant isolates with the Etest method, as recom-
mended by the manufacturer, which includes the use of
Mueller-Hinton 5% sheep’s blood agar (BBL brand, BD
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5% CO2 for 20 to 24 h. Carbon dioxide incubation,
required for the optimal growth of many pneumococci on
solid media, increases erythromycin MICs by ≈1 doubling
dilution and therefore changes the erythromycin MIC
breakpoints to <0.5, susceptible, 1 intermediate, and >2
resistant (14). For the purposes of this study, we combined
isolates with intermediate susceptibility and resistance to
erythromycin as erythromycin-resistant cases for the case-
control study. However, only 1 isolate among these cases
had an erythromycin MIC = 1.0 µg/mL; the remainder had
MICs >1.0 µg/mL.
All pneumococcal isolates were serotyped according to
standard methods by using the Quellung reaction (15–17).
All sera were purchased from the Statens Serum Institut
(WHO Collaborating Centre for Reference and Research
on Pneumococci) and included 14 pooled sera, 62 factor
sera, and 22 type sera.
Data Analysis
We calculated descriptive statistics for case-patients
and controls and compared the distribution of demograph-
ic and clinical characteristics by using χ2 test statistics. We
compared the self-reported patterns of prior antimicrobial
drug exposure between case-patients and controls, distin-
guishing antimicrobial agents that were taken before the
onset of the illness and those taken during the current ill-
ness up to the time of hospitalization.
Multivariable analyses were completed with logistic
regression. We included as candidate risk factors all vari-
ables that were significantly associated with case versus
control status at p<0.10 in bivariate analyses. We devel-
oped a final model using backward elimination, with vari-
ables with p>0.05 eliminated from the model. Associations
between risk factors and macrolide-resistant bacteremic
pneumococcal pneumonia that remained in the model are
presented as odds ratios (ORs) and 95% confidence inter-
vals (CIs). Aseparate model examining patterns of antimi-
crobial drug exposure was constructed restricted to those
participants who reported >1 prior exposure to antimicro-
bial drugs during the 6 months preceding onset of illness.
This study was approved by the institutional review boards
at the University of Pennsylvania School of Medicine and
each participating hospital.
Results
From December 1, 2000, through April 17, 2004, a total
of 1,209 cases of pneumococcal bacteremia among adults
in the 5-county region were identified. Excluding patients
without a concurrent diagnosis of pneumonia, with a con-
current diagnosis of meningitis, residence outside the 5-
county region, or hospitalization within 10 days of the
episode yielded 956 eligible participants. We enrolled 444
(46%). Reasons for nonenrollment included physician
refusal (26%), patient or proxy refusal (36%), and inabili-
ty to locate the patient or family (24%).
Seventy- six patients (17%) had erythromycin-resistant
infections (MIC50 = 8.0 µg/mL, MIC90 = 256 µg/mL, range
1–256 µg/mL) and were selected as the case-patients for
this study (Figure). As expected, 22 of 23 isolates with
erythromycin MICs >64  µg/mL were also clindamycin
resistant (MLSB phenotype), and 49 of 53 isolates with
erythromycin MICs <32 µg/mL were clindamycin suscep-
tible and comprised the M phenotype (18). Compared to
the pneumococcal isolates from patients with erythromy-
cin-susceptible infections, isolates from patients with
erythromycin-resistant infections were more likely to have
reduced susceptibility to penicillin (75% vs. 11%), tetracy-
cline (38% vs. 1%), and trimethoprim-sulfamethoxazole
(62% vs. 10%) (all p<0.0001). However, susceptibility to
fluoroquinolones (specifically levofloxacin) was the same
for erythromycin-resistant and erythromycin-susceptible
isolates (1% of erythromycin-susceptible and -resistant
isolates were resistant to levofloxacin, p = 0.82).
Compared to the erythromycin-susceptible isolates, eryth-
romycin-resistant isolates were more than twice as likely
to belong to 1 of the 7 serotypes contained within the new
pneumococcal conjugate vaccine (45% vs. 22%,
p<0.0001).
Demographic and Clinical Risk Factors
Among potential demographic factors, only race and
ethnicity were significantly associated with erythromycin
resistance. White patients were more likely to have a
resistant infection compared to patients self-reporting
other racial categories (Asian, African American or Black,
and Native Hawaiian or other Pacific Islander) (OR 1.8,
95% CI 1.0–3.1), and Hispanic patients were more likely
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Figure. MIC distribution of resistant isolates. This figure displays
the proportion of resistant isolates at each MIC. Isolates with clin-
damycin susceptibility are analyzed separately from isolates with
clindamycin resistance. The total number of isolates is 76. to have a resistant infection compared to non-Hispanic
patients (OR 3.1, 95% CI 1.1–8.8). Patient age, sex, edu-
cation, income, and urban versus suburban residence were
not significantly associated with the probability of an
erythromycin-resistant infection (Table 1).
Among potential clinical factors, a history of chronic
bronchitis or emphysema was associated with an increased
probability of erythromycin resistance (OR 2.0, 95% CI
1.1–3.4), and a history of stroke was associated with a
reduced probability of resistance (OR 0.2, 95% CI
0.1–0.9). Patient report of receiving influenza vaccination
in the prior year was associated with an increased proba-
bility of resistance (OR 1.7, 95% CI 1.0–2.8). Other coex-
isting conditions, including HIV infection, asthma, and
diabetes mellitus, were not significantly associated with
susceptibility of the pneumococcal isolate (Table 1).
Patient report of any exposure to antimicrobial agents
during the 6 months preceding the episode of bacteremic
pneumococcal pneumonia was associated with a >2-fold
increase in the odds of having an erythromycin-resistant
isolate (OR 2.2, 95% CI 1.3–3.7). Fifty-five percent of
patients with erythromycin-resistant infections did not
report any antimicrobial drug exposures in the preceding 6
months. Among different classes of antimicrobial agents,
prior exposure to macrolides and quinolones was each
associated with an increased probability of macrolide
resistance, but reported exposure to penicillins,
cephalosporins, and tetracyclines was not associated with
an increased probability (Table 2). The major macrolide
drugs reported by patients were azithromycin (58%) and
clarithromycin (30%). The major fluoroquinolone drugs
reported by patients were levofloxacin (49%) and
ciprofloxacin (40%). Physicians provided outpatient med-
ical record information on antimicrobial drug exposure for
342 (77%) of the 444 study participants. Based on physi-
cian report, documented prescription of an antimicrobial
agent in the 6 months preceding the episode of bacteremic
pneumococcal pneumonia was associated with an almost
2-fold increase in the odds of having an erythromycin-
resistant isolate, but this finding did not achieve signifi-
cance (OR 1.7 95% CI 1.0–3.1).
Among patients who reported any prior exposure to
antimicrobial drugs, the probability of macrolide resist-
ance increased with patient report of increasing number of
prior courses of drugs. Patients who reported only 1 prior
course had a 1.5-fold increased odds of a resistant infec-
tion, whereas patients who reported >2 courses of antimi-
crobial agents had a 3.0-fold increased odds of a resistant
infection. In addition, the relationship of antimicrobial
drug exposure to the probability of an erythromycin-resist-
ant infection was time sensitive: patients with such expo-
sure within 3 months of infection had significantly
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exposed during the 4–6 months preceding infection did not
have significantly increased odds of resistant infection.
Finally, among patients who had at least 1 course of drugs,
reporting that they did not finish the prescribed course was
associated with >3-fold increased odds of a resistant infec-
tion compared to that for patients who reported completing
the most recent course of antimicrobial agents (OR 3.5,
95% CI 1.4–8.3).
In multivariable analysis, prior exposure to macrolides
(OR 2.8), prior influenza vaccination (OR 2.0), and
Hispanic ethnicity (OR 4.1) were independently associat-
ed with an increased probability of macrolide resistance; a
history of stroke (OR 0.2) was independently associated
with a reduced probability of macrolide resistance (Table
3). All patients with a macrolide-resistant infection report-
ed >1 of these 4 factors (prior exposure to macrolides,
prior flu shot, Hispanic ethnicity, or no history of stroke).
However, 97% of all study patients reported >1 of these 4
factors (data not shown). Among patients who reported at
least 1 course of an antimicrobial agent in the 6 months
preceding infection, the only significant characteristic of
prior exposure was the patient’s report that he or she failed
to complete the full prescription (OR 3.4, 95% CI 1.2–9.9).
Discussion
In this case-control study of 444 adults with bacteremic
pneumococcal pneumonia, we found that exposure to
macrolides in the 6 months preceding infection, a history
of influenza vaccination in the 12 months preceding infec-
tion, and Hispanic ethnicity were all independently associ-
ated with an increased probability of an erythromycin-
resistant infection. However, most patients with erythro-
mycin-resistant pneumococcal infections did not report
any antimicrobial drug exposures in the 6 months preced-
ing infection.
That prior antibacterial drug exposure is a risk factor
for drug-resistant pneumococcal infections is supported by
mathematical models and most empiric studies. Numerous
studies have suggested a relatively strong association
between prior antimicrobial drug use and the subsequent
development of invasive infections due to penicillin-resist-
ant pneumococcal infections (19–24). A recent case-con-
trol study comparing penicillin-susceptible to penicillin-
nonsusceptible isolates from patients with pneumococcal
bacteremia identified prior exposure to β-lactams, sulfon-
amides, and macrolides as risk factors; fluoroquinolone
exposure was not a risk factor. These risk factors remained
relevant up to 6 months before infection (25). Similarly, in
another recent study of invasive pneumococcal disease
comparing patients with macrolide-resistant isolates to
macrolide-susceptible isolates, exposure to each of the fol-
lowing drugs was associated with an increased probability
of a macrolide-resistant infection: penicillin, trimetho-
prim-sulfamethoxazole, clarithromycin, or azithromycin
(26). While our current study found that exposure to the
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odds of a macrolide-resistant infection, the sample was too
small to separately analyze the risk associated with
different drugs within that class. However, given that
antimicrobial drug exposure is common, research on mod-
ifiable risk factors for drug-resistant pneumococcal infec-
tions needs to focus on different patterns of exposure, both
in terms of specific drugs selected and the dose and dura-
tion of administration. Among patients with a prior expo-
sure to antimicrobial agents, reporting that they did not
complete the course was significantly associated with the
odds of a macrolide-resistant infection. Future studies cor-
relating duration of therapy with risk for colonization with
macrolide-resistant pneumococci would be useful to fur-
ther explore this phenomenon.
Additional risk factors associated with drug-resistant
pneumococcal infections have been reported to include
extremes of age, attendance in daycare, having a house-
hold member in daycare, and coexisting illnesses, particu-
larly HIV infection (4,21,27–29). However, many of these
risk factors may be identified only because they are asso-
ciated with higher probabilities of prior antimicrobial drug
exposure, which may have been incompletely measured by
our questions on prior drug use. In this study, for example,
patients who report prior influenza vaccination may have
increased access to health providers or increased frequen-
cy of respiratory infections, both factors that would likely
increase the probability of prior antimicrobial drug expo-
sure. Similarly, while we asked many questions about prior
antimicrobial drug exposure, the observed association
between erythromycin resistance and Hispanic ethnicity
may be confounded by increased access to antimicrobial
drugs through nontraditional sources (such as markets),
where they may be less readily identified as antimicrobial
agents (30). On the other hand, the identification of antimi-
crobial drug–independent risk factors would suggest that
an additional mechanism, specifically increased exposure
to persons with antimicrobial drug–resistant bacteria, is a
factor promoting the emergence of macrolide-resistant
pneumococcal infections. In this regard, the reduced prob-
ability of resistant infections seen in patients with a histo-
ry of stroke might relate to relative social isolation in this
population, which would reduce exposure to persons car-
rying drug-resistant pneumococci. Finally, some of the
observed associations may be due to random (type I) error
and represent false-positive results.
We did not enroll all patients with bacteremic pneumo-
coccal pneumonia. Therefore, selection bias may have
affected our assessment of different risk factors, particular-
ly if enrollment differed for participants with macrolide-
resistant and –macrolide-susceptible infections. Our
analysis of the drug susceptibility of isolates from nonen-
rolled patients showed that the proportion of erythromy-
cin-resistant isolates was not significantly different
between enrolled and nonenrolled patients (data not
shown). In addition, as pointed out by others, the selection
of control groups affects the interpretation of results (31).
In this study, we used patients with antimicrobial
drug–susceptible pneumococcal infections as the control
group to identify factors that might distinguish patients
with pneumococcal infections at the time of treatment
decisions. Finally, we relied primarily on patient self-
report to identify prior antimicrobial drug exposures and
the patterns of these exposures. We used a multistage, pre-
viously validated approach to measure exposure.
Moreover, patient report is typically the source of informa-
tion for providers at the time of treatment decisions.
Although measurement error may have introduced bias in
our risk estimates, the level of association between prior
antimicrobial drug exposure and the odds of a macrolide-
resistant infection were quantitatively similar when we
used information from outpatient medical records.
More broadly, this study demonstrates that among
patients with pneumococcal disease, patients with self-
reported prior exposure to antimicrobial drugs, particular-
ly macrolides, have an increased probability of infection
with macrolide-resistant pneumococci. In addition, addi-
tional courses of antimicrobial drugs increase the probabil-
ity of a drug-resistant infection. However, most patients
with macrolide-resistant infections did not report any prior
antimicrobial drug exposures. As a result, empiric therapy
should be predominately guided by local susceptibility
data rather than specific host characteristics.
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Appendix
The Delaware Valley Case Control Network includes the fol-
lowing physicians and laboratory directors listed with their
respective hospitals.
Robert Dee, Herbert Auerbach (Abington Memorial
Hospital); Jerry Zuckerman, Ierachmiel Daskal (Albert Einstein
Medical Center); John Bartels, Stephen B. Chasko (Brandywine
Hospital); Albert Keshgegian, Olarae Giger (Main Line Clinical
Laboratory); Peter Spitzer, Bryn Mawr Hospital); Lawrence
Livornese, (Lankenau Hospital); David Trevino (Paoli Hospital);
Abby Huang, David Wright (Central Montgomery Medical
Center); Dorothy Slavin, Mark Ingerman, Jerome Santoro,
Lawrence Livornese, Ru Lin Ko Tung (Chestnut Hill Hospital);
John Roberts, Jim Heald (Chester County Hospital); William
Ravreby, Harvey B. Spector (Crozer Chester Medical Center,
Taylor Hospital); Margaret Hessen (Springfield Hospital);
Lawrence M. Matthews, Margaret Hessen (Delaware County
Memorial Hospital); David Loughran, Rose M. Kenny
(Doylestown Hospital); Donald Marcus, Xiaoli Chen (Elkins
Park Hospital); Richard Tepper, Ila Mirchandani (Jeanes
Hospital); Peter Axelrod (Fox Chase Cancer Center); Donald
Marcus, Howard Elefant (Frankford Hospital Torresdale
Division, Frankford Hospital Bucks County Campus, Frankford
Hospital Frankford Division); Bonnie Rabinowitch, Fernando U.
Garcia (Graduate Hospital); Abby Huang, Irwin Hollander
(Grand View Hospital); Young S. Kim, Christopher Emery
(Hahnemann University Hospital); Robert Dee, Pantaleon Fagel
(Holy Redeemer Hospital and Medical Center); Paul Edelstein
(Hospital of the University of Pennsylvania and Presbyterian
Hospital); Paul McGovern (Presbyterian Hospital); Lorenzo M.
Galindo (Mercy Fitzgerald, Mercy Suburban, Mercy Hospital of
Philadelphia); William McNamee (Mercy Fitzgerald, Mercy
Hospital of Philadelphia); Wayne Miller (Mercy Suburban
Hospital); Robert Measley, Harvey J. Bellin (Methodist
Hospital); David S. Fox, Paul Belser (Montgomery Hospital);
Michael Braffman, John Stern, Gary Stopyra (Pennsylvania
Hospital); Raymond Kovalski, Leonas Bekeris (Phoenixville
Hospital); Raymond Kovalski, Dante DiMarzio (Pottstown
Memorial Hospital); William McNamee, Susan Yaron (Riddle
Memorial Hospital); Lawrence Livornese, Pradeep Bhagat
(Roxborough Memorial Hospital); John Bartels, James Monihan
(Jennersville Regional Medical Center); Robert Measley, John
McCormick (St Agnes Medical Center); Abby Huang, David
Steinberg, (St Luke’s Quakertown); Donald Marcus, Zenon
Gibas, Helen Kroh (St Mary Medical Center); Peter Axelrod,
Allan Truant, Jamshid Moghaddas (Temple University Hospital,
Northeastern Hospital, Episcopal Hospital); Jerry Zuckerman
(Northeastern Hospital); Gregory Kane, Fred Gorestein, Donald
Jungkind (Thomas Jefferson University Hospital); Donald
Stieritz (Philadelphia VA Medical Center); David Loughran,
Manjula Balasubramanian (Warminster Hospital).
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